• Hideyuki Kano, Yan-Hua Su, Hsiu-Mei Wu, Gabriela Simonova, Roman Liscak, Or Cohen-Inbar, Jason P Sheehan, Antonio Meola, Mayur Sharma, Gene H Barnett, David Mathieu, Lucas T Vasas, Anthony M Kaufmann, Rachel C Jacobs, and L Dade Lunsford.
• Department of Neurological Surgery, Center for Image-Guided Neurosurgery, University of Pittsburgh, Pittsburgh, Pennsylvania.
• Neurosurgery. 2019 Jan 1; 84 (1): 227-234.

BackgroundStereotactic radiosurgery (SRS) is a potentially important option for intracranial ependymoma patients.ObjectiveTo analyze the outcomes of intracranial ependymoma patients who underwent SRS as a part of multimodality management.MethodsSeven centers participating in the International Gamma Knife Research Foundation identified 89 intracranial ependymoma patients who underwent SRS (113 tumors). The median patient age was 16.3 yr (2.9-80). All patients underwent previous surgical resection and radiation therapy (RT) of their ependymomas and 40 underwent previous chemotherapy. Grade 2 ependymomas were present in 42 patients (52 tumors) and grade 3 ependymomas in 48 patients (61 tumors). The median tumor volume was 2.2 cc (0.03-36.8) and the median margin dose was 15 Gy (9-24).ResultsForty-seven (53%) patients were alive and 42 (47%) patients died at the last follow-up. The overall survival after SRS was 86% at 1 yr, 50% at 3 yr, and 44% at 5 yr. Smaller total tumor volume was associated with longer overall survival (P = .006). Twenty-two patients (grade 2: n = 9, grade 3: n = 13) developed additional recurrent ependymomas in the craniospinal axis. The progression-free survival after SRS was 71% at 1 yr, 56% at 3 yr, and 48% at 5 yr. Adult age, female sex, and smaller tumor volume indicated significantly better progression-free survival. Symptomatic adverse radiation effects were seen in 7 patients (8%).ConclusionSRS provides another management option for residual or recurrent progressive intracranial ependymoma patients who have failed initial surgery and RT.

31 keywords...

hide…